EXUMA Biotech, formerly known as F1 Oncology, is a clinical-stage biotechnology company discovering and developing CAR-T therapies for solid and liquid tumors.
EXUMA Biotechnology is committed to bringing to market CAR-T therapies for the treatment of cancer.
EXUMA Biotechnology was founded in Nov 2015 and is headquartered in West Palm Beach, Florida. The company has its international affiliates in the Cayman Islands and Shanghai, China.
EXUMA Biotech provides an experienced blend of innovative discovery and translational medicine within a framework of quality standards and regulatory science.
EXUMA Biotechnology's comprehensive, data-driven approach to candidate design and selection provides an optimized and efficient process to select the best CAR composition for a given indication amongst hundreds of thousands of rationally designed combinations, while applying equal innovation to technologies that enable scalability and global patient access to our solutions.
EXUMA Biotechnology is developing logic gated CAR-T platforms to advance TME-restricted cellular therapies for solid tumors, platforms that will allow for same-day, rapid point of care (rPOC) administration for solid or liquid tumors, and highly scalable systems for global therapy deployment, beginning in Asia.
EXUMA Biotechnology is backed by MSD Partners, F1 BioVentures, Sinobioway, Sunterra Capital and others. The company raised $19M in a Series B round on Mar 12, 2020. This brings EXUMA's total funding to $29M to date.